Triangle1.0% IP-001 for injection (NCT06526338)
1.0% IP-001 for injection trial for Hepatocellular Carcinoma (NCT06526338). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with liver-confined hepatocellular carcinoma at intermediate or higher recurrence risk, suitable for microwave ablation, with or without surgery.
The idea: IP-001 is injected into ablated tumors to stimulate an immune response. Patients with up to three tumors receive ablation-based treatment alone or one of two injection volumes. Those with more tumors compare two drug concentrations. Researchers measure recurrence-free survival.
This phase 2 study plans 315 patients. Robert Martin leads at the University of Louisville, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.